Welcome to our dedicated page for Akoya BioSciences news (Ticker: AKYA), a resource for investors and traders seeking the latest updates and insights on Akoya BioSciences stock.
Akoya BioSciences, Inc. (Nasdaq: AKYA) is a leading life sciences technology company pioneering spatial biology solutions that transform discovery, clinical research, and diagnostics. Akoya is committed to advancing the science of imaging with its comprehensive platforms, including PhenoCycler® and PhenoImager®, that perform deep proteomic profiling and spatial phenotyping. These cutting-edge platforms enable researchers to analyze tissue samples with high precision, providing insights into cellular interactions and disease mechanisms.
In 2024, Akoya announced preliminary unaudited revenue for Q4 2023 between $25.5 million and $26.5 million, marking a significant increase from Q4 2022. For the fiscal year 2023, revenues are expected to reach between $95.6 million and $96.6 million.
Akoya's portfolio includes innovative products like PhenoCode™ Panels, PhenoCycler®, and PhenoImager® HT, which support high-throughput and high-parameter tissue analysis. Notably, the company has recently partnered with Thermo Fisher Scientific to enhance its spatial multiomic workflow by integrating ViewRNA technology.
The company's technology has attracted significant attention in the scientific community, with its systems cited in over 1,300 publications as of March 2024. Akoya has also formed strategic partnerships and collaborations, including with the Queensland Spatial Biology Centre and organizations like BostonGene and NeraCare, enhancing the application of its platforms in various fields of research and clinical diagnostics.
Financially, Akoya aims for substantial revenue growth in 2024 with projections exceeding 20%, supported by its robust balance sheet and strategic initiatives like the new Manufacturing Center of Excellence in Marlborough, MA. This facility is expected to streamline operations, improve supply chain efficiency, and meet the growing demand for spatial biology solutions.
If you're a scientist or software engineer passionate about revolutionizing imaging science, Akoya BioSciences offers an exciting environment for innovation. For more information, contact Akoya at info@akoyabio.com.
Akoya Biosciences, known as The Spatial Biology Company, will hold its inaugural Spatial Day on December 15, 2021, at 12 p.m. ET. This event will showcase recent advancements in spatial biology, emphasizing its potential in discovery and clinical research. Key speakers include Akoya's CEO Brian McKelligon and leading experts from renowned institutions. Topics will cover disease biology and the future role of spatial biomarkers in transforming healthcare solutions. Interested participants can register at www.akoyabio.com/spatialday.
Akoya Biosciences (AKYA) reported record Q3 2021 revenue of $13.5 million, a 35% increase year-over-year. Product revenue reached $10.9 million, up 38%, while services generated $2.6 million. Gross profit surged to $8.5 million with a margin of 62.7%. The company installed 33 instruments in Q3, contributing to a total of 651 instruments worldwide. With $120.2 million in cash, Akoya maintains strong growth momentum and raised its full-year revenue guidance to at least $53.8 million.
Akoya Biosciences (Nasdaq: AKYA) announced its participation in the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) scheduled for November 10-14, 2021, in Washington, DC. The company will showcase data on its CODEX® and Phenoptics™ platforms, emphasizing their role in developing spatial phenotypic signatures for immuno-oncology biomarkers. A symposium on November 11 will discuss innovations in spatial biomarkers, featuring experts from various organizations. Attendees can also experience hands-on demonstrations at Akoya's booth.
Akoya Biosciences (Nasdaq: AKYA) announced its participation in two upcoming virtual investor conferences. The first is the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum on November 18, where CEO Brian McKelligon will speak on the future of spatial biology at 1:00 p.m. ET. The second is the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 30 to December 2, featuring a fireside chat with McKelligon and CFO Joe Driscoll, available starting November 22 at 10:00 a.m. ET.
Akoya Biosciences, recognized as The Spatial Biology Company®, announced the formation of the Akoya Imaging Innovators (I²) Network. This initiative aims to advance spatial biology by collaborating with leading researchers in various fields, including oncology and neuroscience, who will utilize Akoya's CODEX technology for single-cell spatial analysis. Members are selected for their innovative contributions, and the program provides access to CODEX systems and support from Akoya's experts, fostering transformative research in spatial phenotyping.
Akoya Biosciences (NASDAQ: AKYA) announced the appointment of Pascal Bamford, PhD, as Senior Vice President of Research and Development and Laboratory Operations, effective October 26, 2021. Dr. Bamford, with extensive experience in laboratory innovations, will drive the growth of Akoya’s spatial biology solutions and enhance the Advanced Biopharma Services (ABS) offerings. Previously, he held senior roles at Exact Sciences and Epic Sciences, contributing to significant product development in clinical diagnostics and oncology.
Akoya Biosciences (Nasdaq: AKYA) will release its Q3 2021 financial results on November 8, 2021, after market close. A conference call to discuss these results is scheduled for 5:00 p.m. ET, accessible via dial-in numbers for domestic and international callers. Akoya, known as The Spatial Biology Company®®, focuses on spatial phenotyping with solutions like CODEX® and Phenoptics™ to enhance research in biology and health by providing insights into cell organization and interactions.
Akoya Biosciences, Inc. (NASDAQ: AKYA) has appointed Dr. Myla Lai-Goldman to its board of directors. With extensive experience in the diagnostics industry, Dr. Lai-Goldman aims to enhance Akoya's efforts in spatial biology, which has potential applications in life sciences. CEO Brian McKelligon expressed excitement about her joining the team as the company enters a new growth phase. Dr. Lai-Goldman's background includes key roles at LabCorp and co-founding GeneCentric Therapeutics, positioning her to drive Akoya's mission of advancing patient care through innovative solutions.
Akoya Biosciences, known as The Spatial Biology Company®, announced its virtual participation in the Morgan Stanley 19th Annual Global Healthcare Conference. The event will feature a fireside chat with CEO Brian McKelligon and CFO Joe Driscoll on September 13, 2021, at 5:00 p.m. ET. A live webcast will be available on Akoya's website for 90 days following the event. Akoya specializes in spatial phenotyping and offers platforms like CODEX® and Phenoptics™ to enhance research in biology and human health.
Akoya Biosciences (Nasdaq: AKYA) reported strong financial results for Q2 2021, achieving total revenue of $13.1 million, a 53% increase from $8.6 million in Q2 2020. Notable growth in reagent sales reached $4.3 million, up from $1.5 million year-over-year. Gross profit was $8.1 million, with a gross profit margin of 62.2%. The company announced significant strategic initiatives, including a partnership with AstraZeneca and the launch of the Imaging Innovators Network, further solidifying its role in spatial biology.
FAQ
What is the current stock price of Akoya BioSciences (AKYA)?
What is the market cap of Akoya BioSciences (AKYA)?
What does Akoya BioSciences, Inc. do?
What are Akoya's core products?
How did Akoya perform financially in 2023?
Who are some of Akoya's key partners?
What recent achievements has Akoya announced?
How many publications have cited Akoya's technology?
What is Akoya's financial outlook for 2024?
What is the significance of the new Manufacturing Center of Excellence?
Who should consider working at Akoya BioSciences?
How can one contact Akoya BioSciences for more information?
